2023 HCMS Scientific Sessions

7:45 AM - 8:30 AM

Registration

Coffee, breakfast, and networking

8:30 AM - 8:45 AM 

Opening Remarks 

Andrew Wang, MD

Sharlene Day, MD

Neal Lakdawala, MD

8:45 AM - 9:15 AM

Lecture: Translating Advances In HFrEF To Non-obstructive HCM-rEF

In this session therapeutic innovation in non-obstructive hypertrophic cardiomyopathy will be contrasted with heart failure with reduced ejection fraction.

Moderated by: Neal Lakdawala, MD; Nosheen Reza, MD ; Eiran Z. Gorodeski, MD

9:15 AM - 9:45 AM

Lecture: Progressive thoughts on exercise in HCM

In this session evolving perspectives about exercise in patients with HCM will be reviewed. 

Moderated by: Lindsay Davis; Michael Emery, MD; Heidi Salisbury, RN

Oral Abstract Presentations 

Investigators will present original science in a rapid fire format submitted to the HCMS Sessions with time for Q&A. 

Predictors of appropriate ICD discharges and the additive role of late gadolinium enhancement in hypertrophic cardiomyopathy - Presented by: Srekar Ravi, MD and Said Alsidawi, MD

Cumulative long-term efficacy and safety of mavacamten treatment in nonobstructive hypertrophic cardiomyopathy: updated interim analysis from the MAVERICK cohort of the MAVA-long-term extension (LTE) study up to 120 weeks - Presented by: Anjali Owens, MD 

Classifying pathogenicity of TPM1 variants of unknown significance using in vitro and in silico approaches - Presented by:  Stuart Campbell, MD 

Moderated by: Ozlem Bilen, MD; Milind Desai, MD

Morning Break 

10:30 AM - 11:00 AM

Lecture: HCM in under-represented populations; Women and Diverse Ancestral Populations

In this session, studies of disparities in HCM care and research will be reviewed.

Moderated by: Jeff Geske, MD; Alex De Feria, MD; Melissa Burroughs, MD

Lecture: After the Lede. Ancillary findings from CMI trials. 

Ancillary findings and sub group analysis from trials of cardiac myosin inhibitors will be reviewed.

Moderated by: Anjali Owens, MD; Andrew Wang, MD

Sara Saberi, MD

11:30 - 12:15 PM

Panel discussion on practical implementation of CMI

Cardiac myosin inhibitors (CMI) are approved, but implementation in clinical practice remains a work in progress. In this session, faculty will present innovative ways of incorporating CMI in the care of patients.

Moderated by: Anna Woo, MD; Heidi Salisbury, RN

Steve Ommen, MD

Matt Martinez, MD

Craig Alpert, MD

Ahmad Masri, MD

12:15 PM - 1:30 PM

Lunch

Break bread with HCM Session faculty in an opportunity to ask questions and share your experiences in an informal setting.

1:00 PM - 1:45 PM

Poster Abstract Presentations 

Design of DISCOVER-HCM: A Registry of Real-world Treatment Patterns and Outcomes of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Presented by:  John Spertus, MD

Impact of a Center of Excellence in Confirming or Excluding a Diagnosis of Hypertrophic Cardiomyopathy- Presented by:  Elizabeth Farrer, BS

Left Atrial Functional Assessment in Hypertrophic Cardiomyopathy Patients Receiving Mavacamten - Presented by:  Janelle Muuse, DO

MyPeak-1: A Phase 1b Study to Evaluate Safety and Efficacy of TN-201, an Adeno-Associated Virus Serotype 9 (AAV9) Investigational Gene Therapy, in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM) - Presented by:  Laura Robertson, MD 

Low Seroprevalence of Neutralizing Antibodies to Adeno-Associated Virus Serotype 9 (AAV9) in Preparation for MyPeak-1, the First-in-Human Study of TN-201, an Investigational AAV9-Mediated Gene Therapy for Individuals with MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM) - Presented by:  Milind Desai, MD 

Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy  - Presented by:  Martin Maron, MD

1:45 PM - 2:15 PM

Panel Discussion: I've found the intermediate biomarker of HCM disease progression!

The session will review potential intermediate phenotypes/biomarkers which could provide prognostic insights into long term disease progression and attendant risks of atrial fibrillation and progressive heart failure. Establishing short term markers of long term disease progression may help to identify disease modifying therapies.

Moderated by: Michael Ayers, MD; Sharon Cresci, MD

Carolyn Ho, MD

John Spertus, MD 

James MacNamara, MD

Sheila Hegde, MD

2:15 PM - 2:45 PM

Lecture: Defining quality HCM care in 2023; SRT and more

It's more than just septal reduction therapy. In this session, methods of measuring and improving the quality of care for patients with HCM will be discussed.

Moderated by: Albree Tower-Rader, MD; Richard Bach, MD ; Daniel Swinstel, MD 

Jim Udelson, MD

2:45 PM - 3:15 PM

Afternoon Break/Posters 

3:15 PM - 3:45 PM

Panel Discussion: Emerging pharmacologic therapies for HCM

In this session, novel applications of established therapies and agents with novel mechanisms of action will be discussed.

Moderated by: Anna Axelson, MD; Matt Wheeler, MD; Scott Solomon, MD

Sharlene Day, MD 

Marc Semigran, MD

Steve Heitner, MD

Amy Sehnert, MD

Lecture: Gene therapies; Overview (101) and HCM specific challenges. Who is the first patient?

In this session, there will be an overview of gene therapies and the discussion of the challenges of applying these therapies for HCM.

Moderated by: Carolyn Ho, MD; Barry Greenberg, MD